

CLAIMS

1. A mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131 corresponding to SEQ ID NO: 1, wherein said mutation is a substitution mutation selected from K130Y and/or I131Y, wherein the protein is an agonist of the CD200 receptor.
2. The protein as defined in claim 1, which comprises one or more additional mutations, wherein the one or more additional mutations is selected from G129I, F128R, and N81K.
3. The protein as defined in claim 1 or claim 2, which comprises an amino acid sequence with at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.
4. The protein as defined in claim 1, comprising the sequence of SEQ ID NO: 12 or SEQ ID NO: 13.
5. The protein as defined in any one of claims 1 to 4, which comprises the extracellular domain (ECD) of said protein having at least 90% sequence identity with an amino acid sequence of SEQ ID NO: 2.
6. The protein as defined in any of claims 1 to 5, comprising the sequence of SEQ ID NO: 3 or SEQ ID NO: 4.
7. The protein as defined in any one of claims 1 to 6, wherein the mutated CD200 protein has a higher affinity for the CD200 receptor compared to a wild type or non-mutated CD200 protein.
8. A fusion protein comprising the protein as defined in any of claims 1 to 7, fused to a non-CD200 protein encoding portion via an optional linker portion.
9. The protein as defined in claim 8, wherein said linker portion is a peptide comprising between 1 and 15 amino acids.
10. The protein as defined in claim 8 or claim 9, wherein said non-CD200 protein encoding portion is an antibody or fragment thereof.

11. The protein as defined in any of claims 8 to 10, wherein said non-CD200 protein encoding portion is an Fc fragment.

12. The protein as defined in any of claims 8 to 11, comprising the sequence of SEQ ID NO: 6 or SEQ ID NO: 7.

13. A polynucleotide encoding a protein as defined in any of claims 1 to 12.

14. A pharmaceutical composition comprising the protein as defined in any of claims 1 to 12.

15. Use of the protein as defined in any of claims 1 to 12, or the composition as defined in claim 14 in the manufacture of a medicament for the treatment of autoimmune disease.